With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
This MSKCC study is making big headlines at ASCO 2017. Patients receiving chemotherapy for metastatic cancer were randomized to standard care versus reporting their problems and symptoms via a web-based tool with a primary outcome of quality of life (QOL). Well, it did more than improve QOL. Median survival was significantly improved by 5 months in the intervention group—a magnitude usually associated with blockbuster drugs. With the caveat of survival outcomes being a post-hoc analysis, this data will feed the growing palliative/supportive care movement in oncology...and for good reason.